JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
- Sponsor
- University of Cologne
- Study ID
- NCT02164500
- Phase
- PHASE2
- Status
- Completed
Conditions
- Recurrent Classical Hodgkin Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ruxolitinib — DRUG
Study Details
The Purpose of this trial is: * to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL * to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL
Key Dates
- Start date
- Oct 31, 2015
- Status verified
- Apr 2020
- Primary completion
- May 17, 2019
- Completion
- May 17, 2019
Study Design
- Enrollment
- 12 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Ruxolitinib
Primary Outcome Measure
overall response rate [ Time Frame: 8 weeks ]